Trust tied to Monopar (MNPR) CEO receives 62,815 shares

Rhea-AI Filing Summary

Monopar Therapeutics Chief Executive Officer and director Chandler Robinson reported an indirect acquisition of 62,815 shares of common stock on a Form 4. The shares were received at $0 per share through a pro rata liquidating distribution from Tactic Pharma, LLC and are held by the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020. Following this transaction, Robinson also reports 85,718 common shares held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Robinson Chandler

(Last) (First) (Middle)

1000 SKOKIE BLVD SUITE 350

(Street)

WILMETTE IL 60091

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Monopar Therapeutics [ MNPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								85,718	D
Common Stock	01/28/2025		J(1)		62,815	A	$0	62,815	I	See Footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Pro rata liquidating distribution from Tactic Pharma, LLC ("Tactic"), of which the reporting person is a non-controlling member. In prior reports, the reporting person reported beneficial ownership of 272,026 shares of Monopar Therapeutics Inc. common stock held by Tactic.

2. Represents shares held by the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020.

	/s/ Quan Vu, Attorney-in-fact	01/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Monopar (MNPR) report for CEO Chandler Robinson?

Monopar CEO Chandler Robinson reported an indirect acquisition of 62,815 common shares. The shares were received at $0 per share via a pro rata liquidating distribution from Tactic Pharma, LLC and are held by the Chandler D. Robinson Irrevocable Trust.

How many Monopar (MNPR) shares did the Chandler D. Robinson Irrevocable Trust receive?

The Chandler D. Robinson Irrevocable Trust received 62,815 Monopar common shares. According to the Form 4, these shares came from a pro rata liquidating distribution by Tactic Pharma, LLC and were reported as indirectly owned by Robinson at a price of $0 per share.

How many Monopar (MNPR) shares does Chandler Robinson hold directly after this filing?

Chandler Robinson reported 85,718 Monopar common shares held directly after the transaction. This direct ownership is shown separately from the 62,815 shares held indirectly through the Chandler D. Robinson Irrevocable Trust referenced in the Form 4 footnotes.

What is the role of Tactic Pharma, LLC in the Monopar (MNPR) Form 4 transaction?

Tactic Pharma, LLC was the source of the 62,815 shares distributed. The filing explains it was a pro rata liquidating distribution from Tactic, where Robinson is a non-controlling member, and earlier reports had shown his beneficial ownership of Monopar shares held by Tactic.

In what capacity is Chandler Robinson related to Monopar (MNPR)?

Chandler Robinson serves as both Chief Executive Officer and director of Monopar Therapeutics. The Form 4 identifies him as an officer with the title Chief Executive Officer and as a director, disclosing his direct and indirect beneficial ownership of Monopar common stock.